Astraea
AI Operating System for Clinical Development
Astraea operates in b2b based in San Francisco, CA, USA.
Profile
Astraea automates clinical trial biometrics from raw study inputs to FDA-ready outputs. The platform handles data normalization, CDISC mapping, SDTM, ADaM, TFLs, QC, and revision workflows in one auditable system, helping Phase II/III sponsors reduce months of manual programming and data management into automated, reviewable execution.
Astraea is positioned in b2b, a segment that rewards a clear, focused offering.
The company is recorded as being based in San Francisco, CA, USA.
The company is listed at the Spring 2026 stage of development.
Recorded headcount: 2 employees.
Directory analysis
Astraea offers an AI-driven operating system that automates the entire clinical trial data workflow, converting raw inputs into FDA-ready outputs. The platform handles data normalization, CDISC mapping, SDTM and ADaM dataset generation, TFL creation, and manages QC and revision processes within a single auditable system. By doing so, it enables Phase II/III sponsors to reduce months of manual programming and data management.
Positioning: Astraea targets the clinical development market with a comprehensive automation solution that could streamline data handling for sponsors. Its focus on auditability and compliance positions it as a potential alternative to traditional manual or fragmented software tools.
Note: Astraea is a San Francisco-based startup with 2 employees, providing AI-powered clinical trial data automation.
Auto-generated directory analysis from public data · updated 7 Oct 2026. Informational only, not investment advice.
| Sector | B2B |
|---|---|
| Headquarters | San Francisco, CA, USA |
| Country | USA |
| Employees | 2 |
| Stage | Spring 2026 |
Website: tryastraea.com
Browse related
Create a free account